drugset / Trial / NCT00130702
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Phase 2
Completed
18 enrolled
Dana-Farber Cancer Institute
Boston Children's Hospital · collabBrigham and Women's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.
Timeline
- Start
- 2005-08
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gefitinib | Small molecule | 750 mg | Oral |